Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$300.08 -0.6%	$293.06	$253.30 ▼ $339.17	$162.35B	0.49	1.84 million shs	2.66 million shs
CPHD Cepheid	$52.95	$0.00	$25.09 ▼ $53.91	N/A	N/A	1.25 million shs	N/A
GILD Gilead Sciences	$112.46 -1.8%	$110.72	$72.43 ▼ $119.96	$142.44B	0.33	5.47 million shs	6.13 million shs
VRTX Vertex Pharmaceuticals	$374.98 -20.6%	$454.92	$373.19 ▼ $519.88	$121.28B	0.44	1.17 million shs	10.72 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.62%	-1.15%	+0.61%	+8.79%	-7.73%
CPHD Cepheid	0.00%	0.00%	0.00%	0.00%	0.00%
GILD Gilead Sciences	-1.79%	-1.55%	+1.06%	+13.71%	+50.29%
VRTX Vertex Pharmaceuticals	-20.60%	-19.95%	-17.52%	-13.76%	-21.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.596 of 5 stars	2.2	3.0	3.3	3.9	3.5	2.5	1.9
CPHD Cepheid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	4.6536 of 5 stars	1.4	3.0	4.2	4.1	3.0	2.5	3.1
VRTX Vertex Pharmaceuticals	4.8898 of 5 stars	4.3	3.0	0.0	3.3	3.8	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.27	2.40% Upside
CPHD Cepheid	0.00	N/A	N/A	N/A
GILD Gilead Sciences	2.81	Moderate Buy	$112.36	-0.09% Downside
VRTX Vertex Pharmaceuticals	2.50	Moderate Buy	$495.21	32.06% Upside

Current Analyst Ratings Breakdown

Latest CPHD, AMGN, GILD, and VRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	VRTX Vertex Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$442.00 ➝ $438.00
8/5/2025	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$520.00 ➝ $490.00
8/5/2025	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$430.00 ➝ $405.00
8/5/2025	VRTX Vertex Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$582.00 ➝ $553.00
8/5/2025	VRTX Vertex Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$557.00 ➝ $530.00
8/5/2025	VRTX Vertex Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$535.00 ➝ $485.00
8/5/2025	VRTX Vertex Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$494.00 ➝ $455.00
8/5/2025	VRTX Vertex Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$550.00 ➝ $478.00
8/5/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$460.00 ➝ $439.00
7/25/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$133.00
7/23/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$252.00 ➝ $261.00

(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.83	$30.19 per share	9.94	$10.93 per share	27.45
CPHD Cepheid	N/A	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$28.75B	4.87	$6.75 per share	16.67	$15.44 per share	7.28
VRTX Vertex Pharmaceuticals	$11.02B	8.74	N/A	N/A	$63.72 per share	5.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	27.38	14.03	2.61	17.39%	176.11%	12.39%	N/A
CPHD Cepheid	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$480M	$4.75	23.68	13.87	0.72	20.76%	51.93%	17.40%	8/7/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	26.80	21.42	N/A	31.86%	24.28%	17.42%	N/A

Latest CPHD, AMGN, GILD, and VRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.99	N/A	N/A	N/A	$6.95 billion	N/A
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
8/4/2025	Q2 2025	VRTX Vertex Pharmaceuticals	$4.24	$4.52	+$0.28	$3.99	$2.90 billion	$2.94 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.17%	N/A	86.86%	14 Years
CPHD Cepheid	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.81%	N/A	66.53%	10 Years
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CPHD, AMGN, GILD, and VRTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
CPHD Cepheid	N/A	N/A	N/A
GILD Gilead Sciences	1.16	1.37	1.23
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
CPHD Cepheid	95.75%
GILD Gilead Sciences	83.67%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
CPHD Cepheid	4.16%
GILD Gilead Sciences	0.27%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
CPHD Cepheid	N/A	N/A	N/A	Not Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable

CPHD, AMGN, GILD, and VRTX Headlines

Recent News About These Companies

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Lowered to $490.00 at Truist Financial

1 hour ago | americanbankingnews.com

BMO Capital Markets Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price

1 hour ago | americanbankingnews.com

Assessing Vertex Pharmaceuticals: Insights From 9 Financial Analysts

2 hours ago | benzinga.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 1-Year Low on Analyst Downgrade

2 hours ago | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Misses Expectations By $0.24 EPS

August 5 at 6:23 PM | marketbeat.com

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

August 5 at 2:23 PM | benzinga.com

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

August 5 at 1:58 PM | benzinga.com

VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal

August 5 at 12:35 PM | zacks.com

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

August 5 at 10:25 AM | investopedia.com

MWA Asset Management Acquires 1,739 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 5 at 7:34 AM | marketbeat.com

Earned Wealth Advisors LLC Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 5 at 7:23 AM | marketbeat.com

J. Safra Sarasin Holding AG Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 5 at 6:57 AM | marketbeat.com

Bank of Nova Scotia Has $13.42 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

August 5 at 6:57 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by US Bancorp DE

August 5 at 6:38 AM | marketbeat.com

Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating

August 5 at 6:18 AM | tipranks.com

Vertex Stock (VRTX) Crashes after Pain-Drug Trial Failure Despite Strong Q2

August 5 at 5:30 AM | tipranks.com

Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating

August 5 at 5:30 AM | tipranks.com

Vertex Pharmaceuticals (VRTX) Stock Dips After Pain Drug Trial Setback

August 5 at 5:30 AM | gurufocus.com

Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...

August 5 at 2:26 AM | gurufocus.com

Vertex Pharmaceuticals: Strong Buy Rating Amid Robust Financials and Market Potential Despite Setbacks

August 4 at 12:58 AM | tipranks.com

Q2 2025 Vertex Pharmaceuticals Inc Earnings Call Transcript

August 4 at 12:10 AM | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHD, AMGN, GILD, and VRTX Company Descriptions

Amgen NASDAQ:AMGN

$300.08 -1.86 (-0.62%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$297.97 -2.11 (-0.70%)

As of 04:11 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Cepheid NASDAQ:CPHD

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Gilead Sciences NASDAQ:GILD

$112.46 -2.05 (-1.79%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$112.88 +0.42 (+0.37%)

As of 04:00 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals NASDAQ:VRTX

$374.98 -97.29 (-20.60%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$376.99 +2.01 (+0.54%)

As of 04:13 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time